# ClinicalTrials.gov record NCT07313761

> PeptideScanner retained ClinicalTrials.gov record NCT07313761 at 2026-08-13T05:52:27.026Z. Its registry update date was 2026-08-07, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.

- Evidence object: `story:clinicaltrials-gov-nct07313761-maridebart-cafraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-08-07
- Source checked: 2026-08-13
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07313761-maridebart-cafraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct07313761-maridebart-cafraglutide-v1.json
- Content SHA-256: `d15daf00bd8bae3f3af23d4060ea8dc8ea540a83304292eb06e5f870f08f7e03`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT07313761 ([`ctg-observation-nct07313761-2026-08-07-e83b3d74dfe0`](#source-ctg-observation-nct07313761-2026-08-07-e83b3d74dfe0))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07313761 at 2026-08-13T05:52:27.026Z. Its registry update date was 2026-08-07, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide. ([`ctg-observation-nct07313761-2026-08-07-e83b3d74dfe0`](#source-ctg-observation-nct07313761-2026-08-07-e83b3d74dfe0))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07313761 at 2026-08-13T05:52:27.026Z. Its registry update date was 2026-08-07, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide. ([`ctg-observation-nct07313761-2026-08-07-e83b3d74dfe0`](#source-ctg-observation-nct07313761-2026-08-07-e83b3d74dfe0))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07313761-2026-08-07-e83b3d74dfe0`](#source-ctg-observation-nct07313761-2026-08-07-e83b3d74dfe0))

## Sources

<a id="source-ctg-observation-nct07313761-2026-08-07-e83b3d74dfe0"></a>
- **ClinicalTrials.gov record NCT07313761 · retained source version 2026-08-07:e83b3d74dfe048cc939dbfd917b586a5a46559f5c3856ba40d9a8b6750899789** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07313761) (`ctg-observation-nct07313761-2026-08-07-e83b3d74dfe0`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07313761." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct07313761-maridebart-cafraglutide-v1.json SHA-256: d15daf00bd8bae3f3af23d4060ea8dc8ea540a83304292eb06e5f870f08f7e03.